Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma.

Levetiracetam extends survival in children with diffuse midline glioma by targeting GABAergic synapses, but not in other glioma subtypes.

• Why it matters: Glioma patients often receive antiseizure medications, but their impact on survival varies across subtypes, creating a need to understand subtype-specific effects and optimize treatment strategies.
• What they did: The study analyzed retrospective clinical data and conducted preclinical experiments, demonstrating that levetiracetam reduces glioma proliferation and GABAergic synaptic transmission specifically in DMG models.
• The result: Findings suggest levetiracetam’s potential as a targeted therapy for DMG by modulating GABAergic synapses, warranting further clinical trials to improve patient outcomes.